Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601585 | 0.90 | KDM4E (0.80) | KDM4EPOLBCA1CA2CA9 | |
| SCHEMBL14987175 | 0.86 | KDM4E (0.74) | KDM4EPOLBCA1CA2CA9 | |
| SCHEMBL29461389 | 0.82 | KDM4E (0.67) | KDM4EPOLBCA1CA2CA9 | |
| SCHEMBL10800648 | 0.76 | ALDH1A1 (0.72) | KDM4EPOLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL22118520 | 0.75 | CA1 (1.00) | KDM4EPOLBCA1CA2CA9 | |
| SCHEMBL29359926 | 0.72 | ALDH1A1 (0.65) | KDM4EPOLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL29362473 | 0.72 | ALDH1A1 (0.65) | KDM4EPOLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL21368796 | 0.71 | GLS (0.76) | KDM4EPOLBALDH1A1MAPK1HSD17B10 | |
| SCHEMBL29423655 | 0.70 | ALDH1A1 (0.63) | KDM4EPOLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL10800392 | 0.69 | RECQL (0.63) | KDM4EMAPTALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12546775-B2 | Peptides, reagents and methods for detecting food allergy | AllerGenis, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250388685-A1 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST | SANOFI BIOTECHNOLOGY (FR) | 2025-12-25 | — | — | US | disclosed |
| US-20250178822-A1 | PREPACKAGED CHARGE OF EDIBLE MATERIAL POWDER, AND BEVERAGE PREPARATION SYSTEM USING SAID CHARGE | CAFFE PASCUCCI TORREFAZIONE S P A (IT) | 2025-06-05 | — | — | US | disclosed |
| CN-119930827-A | Antibodies targeting PSCA and uses thereof | 重庆精准生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12280120-B2 | Tumor-specific cleavable linkers | Xilio Development, Inc. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4489581-A1 | PREPACKAGED CHARGE OF EDIBLE MATERIAL POWDER, AND BEVERAGE PREPARATION SYSTEM USING SAID CHARGE | Caffé Pascucci Torrefazione S.P.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| CN-118946272-A | Pre-packaged sachet of edible material powder and beverage preparation system using the same | 帕斯库奇咖啡烘焙股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024076222-A1 | COMPOSITION FOR REDUCING DROUGHT STRESS COMPRISING CULTURE SOLUTION OF AUREOBASIDIUM PULLULANS AK-10 STRAIN OR EXTRACT OF STRAIN CULTURE SOLUTION, AND METHOD FOR INDUCING DROUGHT STRESS REDUCTION | 전남대학교산학협력단 | 2024-04-11 | — | — | WO | disclosed |
| WO-2023170594-A1 | PREPACKAGED CHARGE OF EDIBLE MATERIAL POWDER, AND BEVERAGE PREPARATION SYSTEM USING SAID CHARGE. | CAFFE' PASCUCCI TORREFAZIONE S.P.A. (IT) | 2023-09-14 | — | — | WO | disclosed |
| US-20230159603-A1 | MASKED IL-12 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230151072-A1 | MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230072822-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | Xilio Development, Inc. | 2023-03-09 | — | — | US | disclosed |
| EP-4001920-A1 | PEPTIDES AND METHODS FOR DETECTING FOOD ALLERGY | AllerGenis, LLC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220155296-A1 | Peptides, Reagents And Methods For Detecting Food Allergy | AllerGenis, Inc. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12546775-B2 | Peptides, reagents and methods for detecting food allergy | HLA-DRB1, IL33, SERPINA6 | KDM4E 4464/4885POLB 3662/4885CA1 3981/4885 |
| US-20250388685-A1 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST | IL4, CCR4, IL1RN | KDM4E 1295/4885POLB 2737/4885CA1 4633/4885 |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | SPPL2B, SPPL2A, CTSL | KDM4E 2739/4885POLB 3204/4885CA1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.